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a b s t r a c t
The rational development of multinuclear arene ruthenium complexes (arene = p-cymene, hexamethyl-
benzene) from generation 1 (G1) and generation 2 (G2) of 4-iminopyridyl based poly(propyleneimine)
dendrimer scaffolds of the type, DAB-(NH2)n (n = 4 or 8, DAB = diaminobutane) has been accomplished
in order to exploit the ‘enhanced permeability and retention’ (EPR) effect that allows large molecules
to selectively enter cancer cells. Four compounds were synthesised, i.e. [{(p-cymene)RuCl2}4G
1] (1),
[{(hexamethylbenzene)RuCl2}4G1] (2), [{(p-cymene)RuCl2}8G2] (3), and [{(hexamethylbenzene)RuCl2}8G2]
(4), by ﬁrst reacting DAB-(NH2)n with 4-pyridinecarboxaldehyde and subsequently metallating the imi-
nopyridyl dendrimers with [(p-cymene)RuCl2]2 or [(hexamethylbenzene)RuCl2]2. The related mononu-
clear complexes [(p-cymene)RuCl2(L)] (5) and [(hexamethylbenzene)RuCl2(L)] (6) were obtained in a
similar manner from N-(pyridin-4-ylmethylene)propan-1-amine (L). The molecular structure of 5 has
been determined by X-ray diffraction analysis and the in vitro anticancer activities of the mono-, tetra-
and octanuclear complexes 1–6 studied on the A2780 human ovarian carcinoma cell line showing a close
correlation between the size of the compound and cytotoxicity.
1. Introduction
The use of transition metal complexes as potential therapeutics
and in diagnostic medicine is of considerable importance and a
number of excellent reviews and books are available [1]. The ﬁeld
stemmed from the discovery of the anticancer activity of the com-
plex cis-diamminedichloroplatinum(II), cisplatin, one of the most
widely used anticancer drugs effective against testicular cancer
and other tumours [2]. Second generation alternatives to cisplatin,
viz. carboplatin and oxaliplatin, are also effective chemotherapeu-
tic agents for certain cancers [3]. Nevertheless, despite the suc-
cesses of cisplatin and related platinum antitumour agents,
research into non-platinum anticancer agents has evolved due to
problems associated with platinum-based chemotherapies. Nota-
bly, the application of cisplatin in the clinic is marred by side-ef-
fects and drug resistance. Perhaps the most distressing side-
effect is that cisplatin-induced frameshift [4] and base substitution
[5] mutations may be responsible for secondary malignancies ob-
served decades after patients have been treated and cured with
this drug. In order to overcome the limitations of platinum based
therapies compounds containing titanium [6], gold [7] and ruthe-
nium [8] centres have been established and some have already en-
tered early clinical trials. From these studies ruthenium
compounds have been shown to display less general toxicity than
their platinum counterparts [9], and like platinum compounds are
also able to interact with DNA and proteins [10]. The majority of
ruthenium compounds evaluated for anticancer activity are coor-
dination compounds with the ruthenium in the +3 oxidation state.
It has been proposed that in this oxidation state ruthenium is less
active and is reduced in vivo to more active ruthenium(II) com-
plexes, a process favoured in the hypoxic environment of a tumour
[11]. However, it should be noted that ruthenium(II) compounds
also exhibit a low general toxicity and since cancer cells can also
become oxidized at certain stages of their growth cycle oxidation
of the ruthenium cannot be excluded [12]. Since p-coordinated
arenes are known to stabilize ruthenium in its +2 oxidation state,
the potential of arene ruthenium(II) complexes as anticancer
agents, and their associated aqueous chemistry, is being increas-
ingly investigated. The ﬁrst complex evaluated of this kind was
[Ru(benzene)(metronidazole)Cl2] which presented a higher activ-
ity compared to the antitumour drug metronidazole itself [13].
More recently the hydrophilic phosphine-containing [Ru(p-cyme-
ne)(pta)Cl2] (pta = 1,3,5-triaza-7-phosphatricyclo [3.3.1.1] decane),
phosphite-containing [Ru(p-cymene)(P-sugar)Cl2] [14], and
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diamine-containing [Ru(arene)(YZ)(Cl)][PF6] (arene = p-cymene or
biphenyl; YZ = chelating diamine) [15] compounds have been
investigated for anticancer activity. A few recent studies describing
polynuclear organometallic Ru complexes with anticancer activity
have been reported. A few dinuclear arene Ru complexes that exhi-
bit a cytotoxic effect against cancer cells are known. Complexes
with sulfoxide [16] and ethylendiamine [17] ligands were found
to be relatively inactive in vitro, whereas pyrone-derived dinuclear
complexes have demonstrated in vitro anticancer activity in the
low lM range [18–20]. The in vitro anticancer activity of the latter
compounds are determined to some extent by their lipophilicity
[20], and their mononuclear analogues are not active in cell cul-
tures [21]. In addition, dinuclear complexes and tri- and tetranu-
clear clusters such as [H3Ru3(benzene)(hexamethylbenzene)2O]+
[22] and [H4Ru4(benzene)4]2+ [23] have been studied in vitro or
in vivo for their activity, and some show promise against cis-
platin-resistant cell lines. These latter compounds are relatively
large and it is not clear how they enter cancer cells. In this respect,
however tumours can be speciﬁcally targeted by exploiting the ‘en-
hanced permeability and retention’ (EPR) effect. The EPR effect is a
phenomenon in which macromolecules can accumulate at the tu-
mour site due to an increase in blood vessel permeability within
diseased tissues compared to normal tissues [24]. The normal
endothelial layer surrounding the blood vessels feeding healthy
tissues restricts the size of molecules that can diffuse from the
blood. In contrast, the endothelial layer of blood vessels in diseased
tissues is more porous providing access to the surrounding tissue.
Furthermore, diseased tissue does not usually have a lymphatic
drainage system so once macromolecules have entered the tissue
they are retained. Indeed, a tetraruthenium cluster was even found
to be highly active against the polio virus without damaging the
host cells, thereby offering the potential of developing highly selec-
tive drugs [23].
In order to exploit size selective uptake of drugs into tumour
cells effectively, large compounds are required, and in recent years,
dendrimers have found potential as molecular tools in biological
applications [25], especially as nano-carriers [26], diagnostic
agents [27] and as chemotherapeutics [28]. Moreover, another
advantage of dendrimers is their multivalency, which leads to in-
creased interaction between a dendrimer-drug conjugate and a
target bearing multiple receptors, further improving the selectivity
to cancer cells. With the aim of reducing the inherent problems re-
lated to cisplatin such as poor water solubility, high toxicity and
side effects, the combination of platinum-based drugs with den-
dritic systems is very appealing. However, transition metal com-
plexes with anticancer activity, based on a dendritic scaffold are
quite rare. Duncan et al. reported the conjugation of cisplatin to
a polyamidoamine (PAMAM) dendrimer, modiﬁed on the periph-
ery with sodium carboxylate functionalities [29]. The dendrimer-
platinate is water soluble and displayed antitumour activity when
administered intravenously against a B16F10 melanoma, whereas
cisplatin was inactive. Using the commercially available butanedi-
amine poly(propyleneimine) dendrimer (DAB(PA)4) which pro-
vides four peripheral amine groups a series of tetranuclear
platinum compounds were synthesised. The cationic compound
[DAB(PA)4-{Pt(NH3)2Cl}4]4+ was designed to overcome cisplatin
resistance [30], while the neutral derivative DAB(PA)4-
{Pt(dmso)(L)}4 (L =meso-1,2-bis(4-ﬂuorophenyl)ethylenediamine)
was prepared to increase selectivity for breast cancer cells [31].
With the established anticancer activity of arene ruthenium com-
plexes and the current interest in dendrimers for biological appli-
cations, we decided to explore the synthesis of multinuclear
ruthenium complexes based on a poly(propyleneimine) scaffold
and investigate their cytotoxicity against A2780 human ovarian
cancer cell line. As far as we are aware these studies are the ﬁrst
to target arene ruthenium compounds using this approach
although tumour targeting of arene ruthenium compounds via
covalent attachment to recombinant human serum albumin via a
pH cleavable linker has been reported [32].
2. Results and discussion
2.1. Synthesis and characterisation of iminopyridyl-functionalised
dendritic ligands G1 and G2
A ﬁrst- (G1) and second-generation (G2) iminopyridyl dendri-
mer based on a poly(propyleneimine) scaffold was synthesised
via a standard Schiff-base reaction. The 4-pyridylimine-functional-
ised dendritic ligands (G1–G2) were synthesised by the reaction of
4-pyridinecarboxaldehyde with DAB-(NH2)n (n = 4, 8 for G1 and G2,
respectively) (Fig. 1). The dendritic ligands are isolated as orange-
yellow oils, in moderate yields. They are soluble in dichlorometh-
ane, chloroform, methanol, diethyl ether and tetrahydrofuran.
The Schiff base condensation reaction is conﬁrmed by appear-
ance of the peak in the range between 8.17 and 8.23 ppm assigned
to the imine protons for G1 and G2. Two distinct doublets
(3J  6.00 Hz) are observed for the aromatic protons on the 4-pyr-
idyl rings. 13C{1H} NMR spectra for both ligands (G1–G2) show sim-
ilar spectra. Aliphatic carbons were seen in the region of 25–
60 ppm and aromatic carbons in the region of 120–150 ppm for
both generations. As expected for both ligands the imine-carbon
was the most deshielded signal at 159 ppm. For both G1 and G2,
the IR spectra show two absorption bands of strong intensity at
1647, 1599 cm1 and are assigned to the (C@N)imine and
(C@N)aromatic vibrations respectively.
2.2. Synthesis and characterisation of ruthenium complexes 1–6
The dinuclear arene ruthenium complexes [(arene)RuCl2]2 (are-
ne = p-cymene, hexamethylbenzene) reactwith thedendritic ligands
G1 and G2 by stirring at room temperature in dichloromethane to
yield theneutral tetranuclear (1–2) andoctanuclear (3–4) ruthenium
metallodendrimers (Fig. 2). The yellow-orange solids (1–4) are
isolated as air-stable solids in high yields (79–98%). The complexes
aresoluble inmostorganic solventssuchasdichloromethane, chloro-
form, ethanol, dimethylsulfoxide, acetone, acetonitrile, diethyl ether
and tetrahydrofuran.
The 1H NMR spectra of 1–4 shows broadened peaks upon com-
plexation of the multinuclear ruthenium moieties. The aliphatic
protons of the dendritic core and side arms occur at similar shifts
to those of the dendritic ligand precursors. Evidence for the coordi-
nation of the ruthenium metal to the aromatic nitrogen atom can
be seen by a shift in the doublet (assigned to aromatic protons
on the carbon adjacent to pyridyl nitrogen atom) from 8.66 to
9.10 ppm. A shift in the signal is due to the electron-withdrawing
effects of the coordinating metal, resulting in the signals being
shifted downﬁeld. There is also no distinct shift in the imine proton
suggesting no coordination at this position. The 1H NMR spectrum
for the second generation complexes (3–4) showed similar shifts to
the ﬁrst generation. This alludes to coordination at the pyridyl
nitrogen only and not the imine nitrogen. This is further conﬁrmed
by IR spectroscopic studies. Infrared spectroscopic studies show a
shift in the (C@N)aromatic peak from a lower wavenumber to a high-
er wavenumber at around 1615 cm1. The (C@N)imine absorption
band remains unchanged at around 1646 cm1. These shifts were
as a direct result of the synergic effect. The second generation den-
dritic complexes show similar trends. The ruthenium functional-
ised dendrimers (1–4) were precipitated with the inclusion of
solvent, trapped between the dendritic arms. The elemental analy-
sis data correlates with the inclusion of 2 molecules and 4 mole-
cules of dichloromethane for 1 and 3, respectively.
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For comparison, the analogous mononuclear ruthenium com-
plexes (5–6) were synthesised. These were prepared by reacting
the ligand, N-(pyridin-4-ylmethylene)propan-1-amine (L), with
the dinuclear arene ruthenium complexes [(arene)RuCl2]2 (are-
ne = p-cymene, hexamethylbenzene) in dichloromethane at room
temperature, see Scheme 1.
The mononuclear ruthenium complexes (5–6) are isolated as
yellow-orange solids in high yields. They are air-stable and soluble
in dichloromethane, chloroform, ethanol, dimethylsulfoxide, ace-
tone, acetonitrile, diethyl ether and tetrahydrofuran. The aromatic
protons adjacent to the pyridyl nitrogen atom appear more down-
ﬁeld than for the uncoordinated ligand (8.66–9.10 ppm), while the
imine protons remain at the same position as for the dendritic li-
gand (8.2 ppm). A shift in the (C@N)aromatic absorption band in
the IR spectrum of 5 and 6 is seen from around 1550–1615 cm-1.
The (C@N)imine absorption band around 1647 cm1 remains con-
stant and conﬁrms that no coordination occurred at this site. The
coordination of the ruthenium metal occurred to the aromatic
nitrogen atom was further conﬁrmed by the X-ray structure anal-
ysis of complex 5.
2 2
Scheme 1. Synthesis of the mononuclear arene ruthenium complexes 5 and 6.
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Fig. 2. Tetra- and octanuclear arene ruthenium dendritic systems 1–4.
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2.3. X-ray diffraction study of complex 5
X-ray quality crystals for complex 5 were obtained by slow dif-
fusion of hexane into a concentrated dichloromethane solution of
5. The molecular structure of 5 shows that, like other arene ruthe-
nium complexes [33], the metal centre adopts a piano-stool, pseu-
do-tetrahedral geometry, with ruthenium coordinated by the
arene ligand, two chlorides and the iminopyridyl ligand. An ORTEP
drawing of 5 is shown in Fig. 3 together with selected bond lengths
and angles.
The distance between the ruthenium atom and the centre of the
C6H4 aromatic ring of the p-cymene ligand is 1.670(4) Å. The Ru–N
and Ru–Cl bond distances in 5 are comparable to those reported in
the pyridine (py) derivatives [(1,3,5-trimethylbenzene)RuCl2(py)]
[34] and [(hexamethylbenzene)RuCl2(py)] [35]. Similarly, the
Cl–Ru–N and Cl–Ru–Cl bond angles of complex 5 [84.8 (2) and
87.0(2)] are similar to those in [(1,3,5-trimethylbenzene)-
RuCl2(py)] and [(hexamethylbenzene)RuCl2(py)]. As suggested
previously, only the aromatic nitrogen atom is found to be coordi-
nated to the ruthenium atom, thus validating the coordination
mode proposed in complexes 1–6.
2.4. Anticancer activity of complexes 1–6
The ability of 1–6 to inhibit cancer cell growth was evaluated
in vitro using the biological MTT assay which measures mitochon-
drial dehydrogenase activity as an indication of cell viability using
the A2780 ovarian cancer cell line. The compounds were incubated
at various concentrations (in triplicate) in the A2780 cells and cell
viability was measured after an incubation period of 72 hours. Each
experiment was conducted in duplicate and the IC50 values (inhibi-
tion of cancer cell growth at the 50% level) listed in Table 1 are cal-
culated as an average over the two experiments.
All compounds display moderate anti-proliferative activity in
the A2780 cell line. While the IC50 values determined are higher
than that of cisplatin, the most active compounds, 3 and 4, are rel-
atively low for ruthenium compounds. These are the ﬁrst examples
of ruthenium-arene-dichloro complexes with an imino-pyridine li-
gand to be tested for in vitro activity. However, analogous hexa-
methylbenzene and p-cymene cyanopyridine complexes have
previously been reported to show signiﬁcant unwinding of super-
coiled DNA and also inhibit haem polymerase activity. In contrast,
[(p-cymene)Ru(pyridine)Cl2] was found to show negligible activity
in the TS/A cell line [36].
There is a clear trend between the size of the dendritic com-
pound and cytotoxicity, i.e. the monoruthenium compounds have
modest cytotoxicity whereas [{(p-cymene)RuCl2}8G2] 3 and
[{(hexamethylbenzene)RuCl2}8G2] 4 are cytotoxic. Based on this
observation, the biological properties of 3 and 4 are worth studying
further as they may be able to target cancerous tissues more effec-
tively than smaller compounds by exploiting the enhanced perme-
ability and retention effect, a property that needs to be evaluated
in vivo. Moreover, the activity shown here for 3 and 4 is not too dis-
similar to that of the multinuclear arene ruthenium adduct of re-
combinant human serum albumin [26], but the facile synthesis




All reagents were purchased either from Aldrich or Fluka and
used as received. [(p-cymene)RuCl2]2, [(hexamethylben-
zene)RuCl2]2 [37] were prepared according to the literature meth-
ods. The NMR spectra were recorded on a Varian Unity 400
spectrometer (1H: 400 MHz, 13C: 100 MHz) or Varian Mercury
300 (1H: 300 MHz, 13C: 75 MHz) at ambient temperature unless
stated otherwise. Infrared (IR) absorptions were measured on a
Perkin-Elmer Spectrum One FT-IR spectrometer in dichlorometh-
ane using NaCl solution cells. Microanalyses were carried out using
a Fisons EA 110 CHNS elemental analyser. For certain dendrimers,
the analyses are outside acceptable limits, and are ascribed to the
encapsulation of solvent molecules and other inorganic salts by
dendritic compounds. Melting points were determined using a Ko-
ﬂer hot stage microscope (Riechart Thermover) and are corrected.
Mass spectrometry was carried out at the University of Stel-
lenbosch on a Waters API Quattro Micro triple quadrupole mass
spectrometer. Data were recorded using Electrospray Ionisation
(ESI) mass spectrometry in the positive-ion mode.
3.2. Synthesis of dendrimers G1 and G2
A solution of 4-pyridinecarboxaldehyde (1.23 mL, 0.129 mmol)
in dry toluene (5.00 mL) was added dropwise to an ice-cooled solu-
tion of DAB-(NH2)4 (1.006 g, 3.18 mmol) in dry toluene (50.0 mL).
The reaction mixture was stirred at room temperature in the pres-
ence of anhydrous MgSO4 (10 g) for 24 h. The slurry was ﬁltered
and the solvent removed by rotary evaporation yielding an orange
residue. The residue was dissolved in dichloromethane (20 mL),
and washed copiously with H2O (6  20 mL). The organic layer
was collected and dried over anhydrous MgSO4. After ﬁltration
by gravity, the solvent removed by rotary evaporation to yield
the product as an oil, which was dried in vacuo.
Fig. 3. Molecular structure of the mononuclear complex 5 showing ellipsoids at the
50% probability level. Selected bond lengths (Å) and angles (): Ru(1)–N(1) 2.128(9),
Ru(1)–Cl(1) 2.406(3), Ru(1)–Cl(2) 2.405(3), N(2)–C(16) 1.34(3), N(2)–C(17) 1.49(3);
N(1)–Ru(1)–Cl(1) 84.8(2), N(1)–Ru(1)–Cl(2) 87.0(2), Cl(1)–Ru(1)–Cl(2) 87.65(12),
C(13)–C(16)–N(2) 115(2), C(16)–N(2)–C(17) 125(2).
Table 1
IC50 values of cisplatin and complexes 1 – 6 on A2780 human ovarian cancer cell line.a
Compounds 1 2 3 4 5 6 cisplatin
IC50 (lM) 43 40 21 20 98 94 1.6
a Maximum error is < ±5 lM.
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3.2.1. Data for dendritic ligand G1
Pale yellow oil, yield 1.48 g (67.9%). 1H NMR (400 MHz, CDCl3):
dppm = 1.42 (m, 4H, CH2), 1.83 (qn, 8H, CH2), 2.38 (br t, 4H, CH2),
2.52 (m, 8H, CH2), 3.63 (t, 8H, 3J = 7.53 Hz, CH2), 7.52 (d, 8H, 3J =
6.04 Hz, Arpyr), 8.23 (s, 4H, imine), 8.63 (d, 8H, 3J = 6.02 Hz,
Arpyr). 13C {1H} NMR (100 MHz, CDCl3): dppm = 25.3, 28.3, 51.7,
54.1, 59.8 (CH2); 121.8, 150.4 (CH, Arpyr); 143.0 (C, Arpyr); 159.0
(CH, imine). IR (NaCl cells, CH2Cl2, cm1): m(imine C@N) 1648 (s),
m(aromatic C@N) 1599 (s). Anal Calc. for C40H52N10. 1/2CH2Cl2: C,
68.00; H, 7.47; N, 19.58. Found: C, 68.42; H, 7.50; N, 20.02%.
3.2.2. Data for dendritic ligand G2
Pale yellow oil, yield 1.47 g (75.4%). 1H NMR (300 MHz, CDCl3):
dppm = 1.39 (br m, 4H, CH2), 1.47 (br m, 8H, CH2), 1.72 (m, 16H,
CH2), 1.94-2.44 (overlapping m, 36H, CH2), 3.56 (br t, 16H,
3J = 6,49 Hz, CH2), 7.48 (d, 16H, 3J = 6.03 Hz, Arpyr), 8.17 (s, 8H,
imine), 8.57 (d, 16H, 3J = 5.99 Hz, Arpyr). 13C {1H} NMR (75 MHz,
CDCl3): dppm = 24.8, 25.2, 28.3, 51.7, 52.2, 52.3, 54.3, 59.8 (CH2);
121.8, 150.4 (CH, Arpyr); 142.9 (C, Arpyr); 159.0 (CH, imine). IR (NaCl
cells, CH2Cl2, cm1): m(imine C@N) 1648 (s), m(aromatic C@N) 1599 (s).
Anal. Calc. for C88H120N22.1/2CH2Cl2: C, 69.54; H, 7.98; N, 20.16.
Found: C, 69.24; H, 8.18; N, 20.49%.
3.3. Synthesis of complexes 1–4
The dimer [(arene)RuCl2]2 (0.35 mmol, 0.213 g for 1;
0.081 mmol, 0.056 g for 2; 0.307 mmol, 0.199 g for 3; 0.248 mmol,
0.168 g for 4) was dissolved in dry dichloromethane (30 mL). To
this was added a solution of the dendritic ligand in dichlorometh-
ane (5 mL): G1 (0.17 mmol, 0.117 g for 1; 0.041 mmol, 0.027 g for
2), and G2 (0.077 mmol, 0.114 g for 3; 0.041 mmol, 0.062 g for 4).
The reaction mixture was allowed to stir at room temperature
for 5 h. The solvent was reduced to 3 mL, and the product was pre-
cipitated with petroleum ether. The resulting yellow–orange pre-
cipitate was ﬁltered, washed with petroleum ether and dried in
vacuo.
3.3.1. [{(p-cymene)RuCl2}4G1)] (1)
Yellow-orange solid, yield 0.26 g (79.1%). M.p.: 165 C (decom-
pose, without melting). 1H NMR (300 MHz, CDCl3): dppm = 1.30 (d,
24H, 3J = 6.87 Hz, CHMe2), 1.47 (br m, 4H, CH2), 1.83 (br m, 8H,
CH2), 2.09 (s, 12H, CH3), 2.44–2.97 (overlapping m, 12H, H2, H3),
2.97 (m, 4H, CHMe2), 3.67 (m, 8H, H5), 5.28 (d, 8H, 3J = 6.09 Hz,
Arp-cy), 5.70 (d, 8H, 3J = 5.70 Hz, Arp-cy), 7.49 (d, 8H, 3J = 6.15 Hz,
Arpyr), 8.20 (s, 4H, imine), 9.06 (d, 8H, 3J = 5.42 Hz, Arpyr). 13C {1H}
NMR (100 MHz, CDCl3): dppm = 18.3, 22.3 (CH3, p-cy), 27.1, 31.5,
51.2, 53.7, 58.8 (CH2), 122.5, 155.3 (CH, pyr); 139.8 (C, pyr), 30.7,
82.1, 83.3 (CH, p-cy); 97.5, 103.3 (C, p-cy); 158.4 (CH, imine). IR
(NaCl cells, CH2Cl2, cm1): m(imine, C@N) 1646 (s), m(pyr, C@N) 1615
(s). Anal. Calc. for C80H108Ru4Cl8N10.11/2CH2Cl2: C, 48.34; H, 5.52;
N, 6.92. Found: C, 48.22; H, 5.15; N, 6.74%. MS (ESI, m/z): 565.0
[M + 4H + 4CH2Cl2 + H2O]4+.
3.3.2. [{(hexamethylbenzene)RuCl2}4G1] (2)
Yellow-orange solid, yield 0.050 g (86.5%). M.p.: 188 C (decom-
pose, without melting). 1H NMR (300 MHz, CDCl3, d ppm): 1.44 (br
m, 4H, CH2), 1.85 (br m, 8H, CH2), 1.97 (s, 72H, CH3), 2.49–2.58
(overlapping m, 12H, CH2), 3.67 (m, 8H, CH2), 7.51 (d, 8H,
3J = 6.4 Hz, Arpyr), 8.23 (s, 4H, imine), 8.78 (d, 8H, 3J = 6.3 Hz, Arpyr).
13C {1H} NMR (75 MHz, CDCl3, d ppm): 15.4 (CH3, HMB); 24.2, 26.2,
51.0, 53.4, 58.2 (CH2); 91.4 (C, HMB); 122.5, 155.0 (CH, pyr); 143.9
(C, pyr); 158.9 (CH, imine). IR (NaCl cells, CH2Cl2, cm1): m(imine, C@N)
1646 (s), m(pyr, C@N) 1614 (s). Anal. Calc. for C88H124Ru4Cl8N10.
CH2Cl2: C, 51.03; H, 6.06; N, 6.69. Found: C, 51.01; H, 5.85; N,
6.39%. MS (ESI, m/z): 635.0 [M3Cl]3+.
3.3.3. [{(p-cymene)RuCl2}8G2] (3)
Yellow-orange solid, yield 0.30 g (98.1%). M.p.: 214 C (decom-
pose, without melting). 1H NMR (300 MHz, CDCl3): dppm = 1.32 (d,
48H, 3J = 6.92 Hz, CHMe2), 1.35–1.48 (overlapping m, 12H, CH2),
1.78 (m, 16H, CH2), 2.09 (s, 24H, CH3), 2.30–2.53 (overlapping m,
36H, CH2), 2.97 (m, 8H, CHMe2), 3.67 (m, 16H, CH2), 5.28 (d, 16H,
3J = 6.02 Hz, Arp-cy), 5.49 (d, 16H, 3J = 6.01 Hz, Arp-cy), 7.49 (d, 16H,
3J = 6.61 Hz, Arpyr), 8.19 (s, 8H, imine), 9.05 (d, 16H, J3 = 6.53 Hz,
Arpyr). 13C {1H} NMR (75 MHz, CDCl3): dppm = 18.2, 22.2 (CH3,
p-cy), 27.1, 38.8, 51.4, 55.2, 58.8 (CH2), 122.5, 155.3 (CH, pyr),
144.2 (C, pyr), 30.6, 82.0, 83.0 (CH, p-cy), 97.4, 103.2 (C, p-cy),
158.3 (CH, imine). IR (NaCl cells, CH2Cl2, cm1): m(imine, C@N) 1646
(s), m(pyr, C@N) 1614 (s). Anal. Calc. for C168H232Ru8Cl16N22.4CH2Cl2:
C, 48.32; H, 5.66; N, 7.21. Found: C, 48.37; H, 6.03; N, 6.61%. MS
(ESI, m/z): 569.0 [M-7Cl + 3CH2Cl2 + CH3CN]7+.
3.3.4. [{(hexamethylbenzene)RuCl2}8G2] (4)
Yellow-orange solid, yield 0.23 g (91.7%). M.p.: 194 C (decom-
pose, without melting). 1H NMR (400 MHz, CDCl3, d ppm): 1.31
(br m, 4H, CH2), 1.63 (br m, 8H, CH2), 1.87 (m, 8H, CH2), 1.99 (s,
144H, CH3), 2.15–2.38 (overlapping m, 24H, CH2), 2.50 (m, 4H,
CH2,), 2.60 (m, 16H, CH2), 3.69 (m, 16H, CH2), 7.54 (d, 16H,
3J = 6.0 Hz, Arpyr), 8.23 (s, 8H, imine), 8.78 (d, 16H, 3J = 5.6 Hz, Arpyr).
13C {1H} NMR (100 MHz, CDCl3, d ppm): 15.4 (CH3, HMB); 25.3–
58.9 (CH2), 91.4 (C, HMB), 122.5, 155.0 (CH, pyr); 144.1 (C, pyr);
158.9 (C, imine). IR (NaCl cells, CH2Cl2, cm1): m(imine, C@N) 1646
(s), m(pyr, C@N) 1613 (s). Anal. Calc. for C184H264Ru8Cl16N22.2CH2Cl2:
C, 51.60; H, 6.24; N, 7.12. Found: C, 51.69; H, 6.43; N, 6.82%. MS
(ESI, m/z): 631.0 [M-7Cl + 5CH2Cl2 + 2CH3CN]7+.
3.4. Synthesis of the mononuclear complexes 5 and 6
The N-(pyridin-4-ylmethylene)propan-1-amine (L), was pre-
pared by the reaction of 4-pyridinecarboxaldehyde (0.107 g,
0.723 mmol for 5; 0.030 g, 0.200 mmol for 6) with n-propylamine
in diethyl ether. [(p-cymene)RuCl2]2 (0.223 g, 0.362 mmol) or
[(hexamethylbenzene)RuCl2]2 (0.068 g, 0.100 mmol) was dissolved
in dry dichloromethane (30 mL). A solution of the N-(pyridin-4-
ylmethylene)propan-1-amine (0.107 g, 0.723 mmol) in dry dichlo-
romethane (5 mL) was added dropwise and the reaction mixture
was allowed to stir for 5 hours. The solvent was reduced to approx-
imately 3 mL, and the product was precipitated with petroleum
ether. The orange-yellow precipitate was washed with petroleum
ether and dried in vacuo.
3.4.1. [(p-cymene)RuCl2(L)] (5)
Yellow–orange solid, yield 0.15 g (91.1%). M.p.: 163-166 oC. 1H
NMR (400 MHz, CDCl3): dppm = 0.97 (t, 3H, 3J = 7.39 Hz, CH3), 1.32
(d, 6H, 3J = 6.93 Hz, CHMe2), 1.75 (m, 2H, CH2), 2.11 (s, 3H, CH3),
3.00 (m, 1H, CHMe2), 3.66 (t, 2H, 3J = 6.47 Hz, CH2), 5.23 (d, 2H,
3J = 5.93 Hz, Arp-cy), 5.45 (d, 2H, 3J = 5.92 Hz, Arp-cy), 7.60 (d, 2H, 3J
= 6.53 Hz, Arpyr), 8.27 (s, 1H, imine), 9.10 (d, 2H, 3J = 6.43 Hz, Arpyr).
13C {1H} NMR (100 MHz, CDCl3): dppm = 11.8 (CH3), 18.2, 22.3 (CH3,
p-cy), 23.8, 63.6 (CH2), 30.7, 82.2, 83.1 (CH, p-cy), 97.3, 103.6 (C, p-
cy), 122.5, 155.3 (CH, pyr), 144.6 (C, pyr), 157.3 (CH, imine). IR
(NaCl cells, CH2Cl2, cm1): m(imine, C@N) 1647 (s), m(pyr, C@N) 1615
(s). Anal. Calc. for C19H26RuCl2N2: C, 50.22; H, 5.77; N, 6.16. Found:
C, 49.96; H, 5.38; N, 5.99%. MS (ESI, m/z): 419.1 [MCl]+.
3.4.2. [(hexamethylbenzene)RuCl2(L)] (6)
Orange solid, yield 0.15 g (91.1%). M.p.: 139 oC (decompose,
without melting). 1H NMR (400 MHz, CDCl3, d ppm): 0.96 (t, 3H,
3J = 7.4 Hz, CH3), 1.74 (m, 2H, CH2), 2.03 (s, 18H, CH3), 3.66 (t, 2H,
3J = 6.9 Hz, CH2), 7.57 (d, 2H, 3J = 6.4 Hz, Arpyr), 8.26 (s, 1H, imine),
8.86 (d, 2H, 3J = 6.2 Hz, Arpyr). 13C {1H} NMR (100 MHz, CDCl3, d
ppm): 11.8 (CH3), 15.4 (CH3, HMB), 23.8, 63.6 (CH2), 91.4 (C,
5
HMB), 122.5, 155.1 (CH, pyr), 144.2 (C, pyr), 157.5 (CH, imine). IR
(NaCl cells, CH2Cl2, cm1): m(imine, C@N) 1646 (s), m(pyr, C@N) 1614
(s). Anal. Calc. for C21H30RuCl2N2: C, 52.28; H, 6.27; N, 5.81. Found:
C, 51.84; H, 5.94; N, 5.47%. MS (ESI, m/z): 447.1 [MCl]+.
3.5. X-ray crystallography
X-ray data for 5; C19H26Cl2N2Ru, M = 454.39 gmol1, mono-
clinic, P 21/c (no 14), a = 18.246(3), b = 15.057(2), c =
7.3464(11) Å, b = 101.360(14), U = 1978.7(5) Å3, T = 173 K, Z = 4,
l (Mo Ka) = 1.065 mm1, 3530 reﬂections measured, 1316 unique
(Rint = 0.2154) which were used in all calculations. The ﬁnalwR (F2)
was 0.1830 (all data. The data were measured using a Stoe Image
Plate Diffraction system equipped with a / circle goniometer, using
Mo Ka graphite monochromated radiation (k = 0.71073 Å) with /
range 0–200, increment of 1.0, DmaxDmin = 12.45–0.81 Å. The
structure was solved by direct methods using the program SHELXS-97
[38]. The reﬁnement and all further calculations were carried out
using SHELXL-97 [39]. The hydrogen atomswere included in calculated
positions and treated as riding atoms using the SHELXL default param-
eters. All non-H atoms were reﬁned anisotropically, using weighted
full-matrix least-square on F2. Fig. 3 was drawn with ORTEP [40].
3.6. Cytotoxicity study
While imine bonds are susceptible to hydrolysis, the presence of
the aromatic substituent together with a possible dendrimer effect
reduces the rate of hydrolysis, and for the compounds studied here-
in only a slowdecomposition is observed. ThehumanA2780ovarian
cancer cell line was obtained from the European Collection of Cell
Cultures (Salisbury, UK). Cells were grown routinely in RPMI med-
ium containing glucose, 5% foetal calf serum (FCS) and antibiotics
at 37 C and 5% CO2. Cytotoxicity was determined using theMTT as-
say (MTT = 3(4,5dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazo-
lium bromide). Cells were seeded in 96-well plates as monolayers
with 100 lL of cell solution (approximately 20,000 cells) per well
and pre-incubated for 24 hours in medium supplemented with
10% FCS. Compounds were prepared as DMSO solution then dis-
solved in the culturemedium and serially diluted to the appropriate
concentration, to give a ﬁnal DMSO concentration of 0.5%. One
hundred micro litre of drug solution was added to each well and
the plates were incubated for another 72 h. Subsequently, MTT
(5 mg/mL solution) was added to the cells and the plates were
incubated for a further 2 h. The culture medium was aspirated,
and the purple formazan crystals formed by the mitochondrial
dehydrogenase activity of vital cells were dissolved in DMSO. The
optical density, directly proportional to the number of surviving
cells, was quantiﬁed at 540 nm using a multiwell plate reader
and the fraction of surviving cells was calculated from the absor-
bance of untreated control cells. Evaluation is based on means from
two independent experiments, each comprising 3 microcultures
per concentration level.
Acknowledgements
Financial support from the FondsNational Suisse de la Recherche
Scientiﬁque, the University of Cape Town, the National Research
Foundation (NRF) of South Africa, Anglo Platinum Corporation and
a generous loan of ruthenium chloride hydrate from Johnson Mat-
they Technology Centre are gratefully acknowledged.
Appendix A. Supplementary material
CCDC 723508 (5) contains the supplementary crystallographic
data for this paper. These data can be obtained free of charge from
The Cambridge Crystallographic Data Centre via www.ccdc.cam.a-
c.uk/data_request/cif. Supplementary data associated with this
article can be found, in the online version, at doi:10.1016/
j.jorganchem.2009.06.028.
References
[1] (a) C.X. Zhang, S.J. Lippard, Curr. Opin. Chem. Biol. 7 (2003) 481;
(b) L. Ronconi, P.J. Sadler, Coord. Chem. Rev. 251 (2007) 1633;
(c) C. Orvig, M.J. Abrams, Chem. Rev. 99 (1999) 2201;
(d) G. Jaouen (Ed.), Bioorganometallics, Wiley-VCH, Weinheim, 2006;
(e) C.J. Jones, J.R. Thornback (Eds.), Medicinal Application of Coordination
Chemistry, RSC Publishing, Cambridge, 2007;
(f) C.S. Allardyce, A. Dorcier, C. Scolaro, P.J. Dyson, Appl. Organometal. Chem.
19 (2005) 1.
[2] (a) B. Rosenberg, L. Van Camp, J.E. Trosko, V.H. Mansour, Nature 222 (1969)
385;
(b) B. Lippert (Ed.), Cisplatin Chemistry and Biochemistry of a Leading
Anticancer Drug, VCHA & Wiley-VCH, Zurich, 1999.
[3] M. Galanski, M.A. Jakupec, B.K. Keppler, Curr. Med. Chem. 12 (2005) 2075.
[4] K.S. Anderson, Mutat. Res. 67 (1979) 209.
[5] D.J. Beck, R.R. Brubaker, Mutat. Res. 27 (1975) 181.
[6] (a) B.K. Keppler, C. Friesen, H.G. Moritz, H. Vongerichten, E. Vogel, Struct.
Bonding 78 (1991) 97;
(b) C.V. Christodoulou, D.R. Ferry, D.W. Fyfe, A. Young, J. Doran, T.M. Sheehan,
A. Eliopoulos, K. Hale, J. Baumgart, G. Sass, D.J. Kerr, J. Clin. Oncol. 16 (1998)
2761;
(c) M. Hogan, J. Claffey, C. Pampillon, M. Tacke, Med. Chem. 4 (2008) 91.
[7] (a) M.J. McKeage, L. Maharaj, S.J. Berners-Price, Coord. Chem. Rev. 232 (2002)
127;
(b) N. Pillarsetty, K.K. Katti, T.J. Hoffman, W.A. Volkert, K.V. Katti, H. Kamei, T.
Koide, J. Med. Chem. 46 (2003) 1130;
(c) F. Caruso, M. Rossi, J. Tanski, C. Pettinari, F. Marchetti, J. Med. Chem. 46
(2003) 1737;
(d) L. Messori, F. Abbate, G. Marcon, P. Orioli, M. Fontani, E. Mini, T. Mazzei, S.
Carotti, T. O’Connell, P. Zanello, J. Med. Chem. 43 (2000) 3541;
(e) R.G. Buckley, A.M. Elsome, S.P. Fricker, G.R. Henderson, B.R.C. Theobald, R.V.
Parish, B.P. Howe, L.R. Kelland, J. Med. Chem. 39 (1996) 5208;
(f) G. Marcon, S. Carotti, M. Coronnello, L. Messori, E. Mini, P. Orioli, T. Mazzei,
M.A. Cinellu, G. Minghetti, J. Med. Chem. 45 (2002) 1672;
(g) M. Viotte, B. Gautheron, M.M. Kubicki, I.E. Nifant’ev, S.P. Fricker, Met.-
Based Drugs 2 (1995) 311.
[8] (a) C.G. Hartinger, S. Zorbas-Seifried, M.A. Jakupec, B. Kynast, H. Zorbas, B.K.
Keppler, J. Inorg. Biochem. 100 (2006) 891;
(b) W.H. Ang, P.J. Dyson, Eur. J. Inorg. Chem. (2006) 4003;
(c) C.G. Hartinger, M.A. Jakupec, S. Zorbas-Seifried, M. Groessl, A. Egger, W.
Berger, H. Zorbas, B.K. Keppler, Chem. Biodiversity 5 (2008) 2140.
[9] (a) M.J. Clarke, Chem. Rev. 99 (1999) 2511;
(b) M.J. Clarke, Coord. Chem. Rev. 236 (2003) 209. and references cited therein.
[10] (a) I.W. McNae, K. Fishburne, A. Habtemariam, T.M. Hunter, M. Melchart, F.
Wang, M.D. Walkinshaw, P.J. Sadler, Chem. Commun. (2004) 1786;
(b) Y.N.V. Gopal, D. Jayaraju, A.K. Kondapi, Biochem. 38 (1999) 4382;
(c) Y.N.V. Gopal, N. Konuru, A.K. Kondapi, Arch. Biochem. Biophys. 401 (2002)
53;
(d) F. Wang, J. Xu, A. Habtemariam, J. Bella, P.J. Sadler, J. Am. Chem. Soc. 127
(2005) 17734;
(e) A.R. Timerbaev, C.G. Hartinger, S.S. Aleksenko, B.K. Keppler, Chem. Rev. 106
(2006) 2224.
[11] M.J. Clarke, S. Bitler, D. Rennert, M. Buchbinder, A.D. Kelman, J. Inorg. Biochem.
12 (1980) 79.
[12] P.J. Dyson, G. Sava, Dalton Trans. (2006) 1929.
[13] L.D. Dale, J.H. Tocher, T.M. Dyson, D.I. Edwards, D.A. Tocher, Anti-Cancer Drug
Des. 7 (1992) 3.
[14] (a) C.S. Allardyce, P.J. Dyson, D.J. Ellis, S.L. Heath, Chem. Commun. (2001)
1396;
(b) C. Scolaro, A. Bergamo, L. Brescacin, R. Delﬁno, M. Cocchietto, G. Laurenczy,
T.J. Geldbach, G. Sava, P.J. Dyson, J. Med. Chem. 48 (2005) 4161.
[15] (a) R.E. Morris, R.E. Aird, P.S. Murdoch, H. Chen, J. Cummings, N.D. Hughes, S.
Parsons, A. Parkin, G. Boyd, D.I. Jodrell, P.J. Sadler, J. Med. Chem. 44 (2001)
3616;
(b) T. Burgarcic, A. Habtemariam, J. Stepankova, P. Heringova, J. Kasparkova,
R.J. Deeth, R.D.L. Johnstone, A. Prescimone, A. Parkin, S. Parsons, V. Brabec, P.J.
Sadler, Inorg. Chem. 47 (2008) 11470.
[16] L.A. Huxham, E.L.S. Cheu, B.O. Patrick, B.R. James, Inorg. Chim. Acta 352 (2003)
238.
[17] H. Chen, J.A. Parkinson, O. Novakova, J. Bella, F. Wang, A. Dawson, R. Gould, S.
Parsons, V. Brabec, P.J. Sadler, Proc. Natl. Acad. Sci. 100 (2003) 14623.
[18] M.G. Mendoza-Ferri, C.G. Hartinger, R.E. Eichinger, N. Stolyarova, M.A. Jakupec,
A.A. Nazarov, K. Severin, B.K. Keppler, Organometallics 27 (2008) 2405.
[19] M.G. Mendoza-Ferri, C.G. Hartinger, A.A. Nazarov, W. Kandioller, K. Severin,
B.K. Keppler, Appl. Organomet. Chem. 22 (2008) 326.
[20] M.G. Mendoza-Ferri, C.G. Hartinger, M.A. Mendoza, M. Groessl, A.E. Egger, R.E.
Eichinger, J.B. Mangrum, N.P. Farrell, M. Maruszak, P.J. Bednarski, F. Klein, M.A.
Jakupec, A.A. Nazarov, K. Severin, B.K. Keppler, J. Med. Chem. 52 (2009) 916.
6
[21] P.J. Dyson, Nature 458 (2009) 389.
[22] B. Therrien, W.H. Ang, F. Chérioux, L. Vieille-Petit, L. Juillerat-Jeanneret, G.
Süss-Fink, P.J. Dyson, J. Clust. Sci. 18 (2007) 741.
[23] C.S. Allardyce, P.J. Dyson, D.J. Ellis, P.A. Salter, R. Scopelliti, J. Organomet. Chem.
668 (2003) 35.
[24] D.F. Baban, D. F, L.W. Seymour, Adv. Drug Delivery Rev. 34 (1998) 109.
[25] [a] U. Boas, J. B. Christensen, P. M. H. Heegaard, Dendrimers in Medicine and
Biotechnology: New Molecular Tools, RSC Publishing, 2006.;
(b) C.C. Lee, J.A. MacKay, J.M.J. Fréchet, F.C. Szoka, Nature Biotech. 23 (2005)
1517;
(c) D.A. Tomalia, L.A. Reyna, S. Svenson, Biochem. Soc. Trans. 35 (2007)
61.
[26] (a) F. Aulenta, W. Hayes, S. Rannard, Eur. Polym. J. 39 (2003) 1741 (and
references therein);
(b) Y. Cheng, J. Wang, T. Rao, X. He, T. Xu, Front. Biosci. 13 (2008) 1447.
[27] J.B. Wolinsky, M.W. Grinstaff, Adv. Drug Deliv. Rev. 60 (2008) 1037 (and
references therein).
[28] (a) A. Agarwal, S. Saraf, A. Asthana, U. Gupta, V. Gajbhiye, N.K. Jain, Int. J.
Pharm. 350 (2008) 3;
(b) E.R. Gillies, J.M.J. Fréchet, Drug Discov. Today 10 (2005) 35;
(c) M. Liu, J.M.J. Fréchet, PSTT 2 (1999) 393;
(d) S.-G. Sampathkumar, K.J. Yarema, in: C.S.S.R. Kumar (Ed.), Nanomaterials
for Cancer Diagnosis, vol. 7, 2007.
[29] N. Malik, E.G. Evagorou, R. Duncan, Anti-Cancer Drugs 10 (1999) 767.
[30] B.A.J. Jansen, J. van des Zwan, J. Reedijk, H. den Dulk, J. Brouwer, Eur. J. Inorg.
Chem. (1999) 1429.
[31] T. Kapp, A. Dullin, R. Gust, J. Med. Chem. 49 (2006) 1182.
[32] W.H. Ang, E. Daldini, L. Juillerat-Jeannerat, Paul J. Dyson, Inorg. Chem. 46
(2007) 9048.
[33] B. Therrien, Coord. Chem. Rev. 253 (2009) 493.
[34] L. Carter, D.L. Davies, J. Fawcett, D.R. Russell, Polyhedron 12 (1993) 1123.
[35] A.J. Steedman, A.K. Burrell, Acta Crystallogr. Sect. C 53 (1997) 864.
[36] C.A. Vock, C. Scolaro, A.D. Phillips, R. Scopelitti, G. Sava, P.J. Dyson, J. Med.
Chem. 49 (2006) 5552.
[37] (a) M.A. Bennett, A.K. Smith, J. Chem. Soc., Dalton Trans. (1974) 233;
(b) M.A. Bennett, T.W. Matheson, G.B. Robertson, A.K. Smith, P.A. Tucker,
Inorg. Chem. 19 (1980) 1014;
(c) M.A. Bennett, T.N. Huang, T.W. Matheson, A.K. Smith, Inorg. Synth. 21
(1982) 74.
[38] G.M. Sheldrick, Acta Crystallogr. A46 (1990) 467.
[39] G. M. Sheldrick, SHELXL-97, University of Göttingen, Göttingen Germany, 1999.
[40] L.J. Farrugia, J. Appl. Cryst. 30 (1997) 565.
7
